Management of Type 2 Diabetes - Methods for Addition of Prandial to Basal Insulin [0.03%]
2型糖尿病的餐时胰岛素增敏 basal insulin plus prandial insulin 的添加方法
W Rodbard Helena,Boris Karolicki
W Rodbard Helena
As glycaemic control deteriorates with the progression of type 2 diabetes, treatment guidelines advocate starting basal insulin therapy, and then progressing to a basal-bolus regimen as needed. Nevertheless, although timely intensification ...
Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes [0.03%]
临床试验：钠葡萄糖共转运体2抑制剂治疗2型糖尿病的血糖控制与心血管结局的关系
Rene A Oliveros,Son V Pham,Steven R Bailey et al.
Rene A Oliveros et al.
Currently available medications for the treatment of type 2 diabetes have limitations, and many patients do not achieve glycaemic control. Recently, a new approach has emerged using sodium glucose co-transporter 2 (SGLT2) inhibitors that de...
Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema [0.03%]
糖尿病黄斑水肿患者的DEXA植入治疗效果分析
Marco Dutra Medeiros,Micol Alkabes,Paolo Nucci
Marco Dutra Medeiros
Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and ot...
Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes [0.03%]
皮肤自体荧光：一种评估心血管风险和糖尿病风险的非侵入性检测方法
Alin Stirban,Lutz Heinemann
Alin Stirban
The results of the Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) study have strengthened the 'glycaemic memory' concept, postulating that the quality of metabolic control over ...
Chantal Mathieu,Lut Overbergh on behalf of the NAIMIT consortium
Chantal Mathieu
NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading...
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous? [0.03%]
胰岛素与GLP-1受体激动剂联合治疗2型糖尿病的前景——是否有优势？
Baptist Gallwitz
Baptist Gallwitz
Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with i...
Bone Involvement in Primary Hyperparathyroidism and Changes After Parathyroidectomy [0.03%]
原发性甲状旁腺功能亢进伴骨病变及手术治疗后变化
Lars Rolighed,Lars Rejnmark,Peer Christiansen
Lars Rolighed
Parathyroid hormone (PTH) is produced and secreted by the parathyroid glands and has primary effects on kidney and bone. During the pathological growth of one or more parathyroid glands, the plasma level of PTH increases and causes primary ...
Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern [0.03%]
人类免疫缺陷病毒患者的骨质疏松症-一个新兴的临床问题
Filippo Maffezzoni,Teresa Porcelli,Ioannis Karamouzis et al.
Filippo Maffezzoni et al.
The advent of highly active anti-retroviral therapy (HAART) has significantly improved the survival of human immunodeficiency virus (HIV)-infected patients transforming the HIV infection from a fatal illness into a manageable chronic diseas...
Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature [0.03%]
阿狄森病的双释放氢化可的松治疗-文献综述
Roberta Giordano,Federica Guaraldi,Rita Berardelli et al.
Roberta Giordano et al.
In patients with adrenal insufficiency, glucocorticoids (GCs) are insufficiently secreted and GC replacement is essential for health and, indeed, life. Despite GC-replacement therapy, patients with adrenal insufficiency have a greater cardi...
Frederico Costa,Brenda Gumz
Frederico Costa
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years. Octreotide is a somatostatin analogue used in the treatment of NETs, and its use in clinical trials has been as...